Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis

Efficacy of zinc-carnosine chelate compound, Polaprezinc, enemas in patients with ulcerative colitis - Efficacy of Polaprezinc enema in UC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008967

Enrollment

Registered

2012-09-24

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Interventions

Polaprezinc group: Polaprezinc enema contained 150 mg of Polaprezinc suspension in tap water (total volume 100 mL) daily for one week Placebo group: 100 mL tap water enema daily for one week

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Moderate to severe active ulcerative colitis patients who undergo usual induction therapy with a mesalazine, a corticosteroid, and intravenous hyperalimentation.

Exclusion criteria

Exclusion criteria: Key exclusion criteria: (1) Patients who attend to another clinical trial (2) Patients who is disqualified by physician's assessment (3) Patients who have serious complications (4) Patients who have allergic reaction to Polaprezinc

Design outcomes

Primary

Measure	Time frame
The primary end point was a clinical response at week 1.	—

Secondary

Measure	Time frame
Secondary end points were a mucosal healing and a pathological response at week 1.	—

Countries

Japan

Contacts

Public ContactMasayuki Saruta

The Jikei University School of Medicine Division of Gastroenterology and Hepatology

03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026